Menopause Care Shifts Toward Individualized Treatment
Women with menopause symptoms now have updated guidance that weighs personal history and both hormonal and non-hormonal options.
Updated on Nov. 10, 2026 in Women’s Health
The American College of Obstetricians and Gynecologists published new menopause care recommendations in the November 2026 issue of Obstetrics & Gynecology. The guidance urges clinicians to tailor treatment to each woman's symptoms, medical history and risk factors, and covers both hormonal and non-hormonal options.
Why it matters
Menopause symptoms such as hot flashes, night sweats, sleep disruption and mood changes can significantly affect daily life, yet menopause remains a taboo subject in many societies, so many women struggle without seeking care. The guidance arrives as the U.S. Food and Drug Administration moves to remove certain boxed warnings from menopause hormone therapy labeling.
The new recommendations are clinical practice guidance from ACOG rather than a single trial, and they emphasize individualized care. Population estimates place menopause onset around age 50 to 51, with roughly 12% of women reaching it before 45 and about 3.5% developing premature ovarian insufficiency before 40.
The players
American College of Obstetricians and Gynecologists (ACOG)
ACOG is the professional society for obstetricians and gynecologists, setting clinical practice guidance on women's reproductive and midlife health.
U.S. Food and Drug Administration (FDA)
The FDA regulates prescription drug labeling, including hormone therapy products used to treat menopause symptoms.
National Institutes of Health (NIH)
The NIH is the U.S. federal agency that funds biomedical research, and it is creating a Women's Health Division.
The details
The guidance asks clinicians to base menopause care on each woman's symptoms, medical history, personal circumstances and the risks of each treatment rather than applying a single standard. It highlights cognitive behavioral therapy, regular physical activity and balanced nutrition as non-pharmaceutical approaches alongside hormonal and non-hormonal medications. The FDA's planned change concerns boxed warnings introduced in 2003 that covered cardiovascular risks, breast cancer and dementia.
Timeline
November 2025: The FDA announced plans to remove certain boxed warnings from menopause hormone therapy products.
2003: Original hormone therapy boxed warnings were introduced.
November 2026: ACOG published its new menopause recommendations in Obstetrics & Gynecology.
Health Landscape
The removal of the 2003 boxed warnings would mark a shift from a broad, one-size-fits-all caution toward individualized prescribing. The ACOG guidance reflects the same direction by emphasizing tailored treatment and a wider set of hormonal and non-hormonal options.
If menopause symptoms such as hot flashes, night sweats or sleep problems are affecting you, the new guidance supports a conversation with your clinician about options that fit your history. Ask whether cognitive behavioral therapy, physical activity or other non-hormonal approaches could be part of your plan alongside any medications.
The takeaway
Menopause care is moving toward individualized decisions based on each woman's symptoms and risks rather than blanket warnings. Bring your symptoms, history and questions about non-hormonal options to your physician when you discuss menopause management.
Further reading
For more on the topic, explore our Women's Health coverage.
